Owkin Overview
Pro stress-test →Owkin is pioneering advanced AI that can explore and formulate hypotheses beyond the limits of the human mind, building an autonomous AI scientist to automate biopharma R&D and support clinical research. Its AI is trained and validated on the world's richest multimodal patient data network, with findings explored through wet lab infrastructure and refined by a global network of leading oncologists and biologists.
Strategic Profile
Pro stress-test →With $300 million in funding and multimodal patient data collected from more than 800 hospitals over a decade, Owkin's patient data-trained AI agents enable comprehensive and clinically relevant insights that more accurately reflect human disease compared to companies focused primarily on laboratory research data. Partnerships with Anthropic and eight of the top 10 global pharma companies underscore Owkin's capabilities.
Competitive Landscape
Pro stress-test →Owkin operates in a growing competitive space with companies like Roche subsidiary Foundation Medicine, Tempus AI, and Caris Life Sciences offering AI technologies that analyze patient samples for cancer therapy selection. Owkin differentiates through its unique access to multimodal patient data from 800+ hospitals and federated learning approach, enabling clinically-grounded rather than lab-only AI training.
Industry Context
Owkin operates in Biological AI platforms.
Key facts
Founded: 2016 · Headquarters: Paris, France · Employees: 388 (as of May 2026) · Revenue: €10.7M (as of Dec 2020) · Market cap: N/A